Trials / Active Not Recruiting
Active Not RecruitingNCT06339138
Identification of Novel High Quality Methylated DNA Markers in Renal Tumors: Whole Methylome Discovery, Tissue Validation, and Feasibility Testing In Blood and Urine, The INQUIRE Study
Identification of Novel High Quality Methylated DNA Markers in Renal Tumors: Whole Methylome Discovery, Tissue Validation, and Feasibility Testing in Blood and Urine
- Status
- Active Not Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 589 (actual)
- Sponsor
- Mayo Clinic · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
This study is being done to collect blood, tissue and urine samples to identify a novel high quality methylated DNA marker in patients with renal tumors.
Detailed description
PRIMARY OBJECTIVES: I. In tissue, to discover and validate DNA methylation markers (MDMs) for detection of malignant renal and urothelial tumors. II. In blood, to assess the accuracy of candidate MDMs from above for detection of malignant renal and urothelial tumors. OUTLINE: This is an observational study. Participants may undergo blood, urine, and tissue sample collection on study. Participants' medical records are also reviewed.
Conditions
- Chromophobe Renal Cell Carcinoma
- Clear Cell Papillary Renal Tumor
- Clear Cell Renal Cell Carcinoma
- Kidney Oncocytoma
- Papillary Renal Cell Carcinoma
- Urothelial Carcinoma
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Non-Interventional Study | Non-interventional study |
Timeline
- Start date
- 2018-06-27
- Primary completion
- 2027-01-31
- Completion
- 2027-01-31
- First posted
- 2024-04-01
- Last updated
- 2025-12-24
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT06339138. Inclusion in this directory is not an endorsement.